BMW

Toba Industries Ltd. (NEX: TBG.H) (the "Company" or "Toba") is pleased to announce the completion of the $1,283,002 financing and reverse takeover of Beijing Marvel Cleansing Supplies Co. Ltd. ("Beijing Marvel"), formerly known as Peking Marvel Cleansing Supplies Co., Ltd. Beijing Marvel is a leading wet wipes manufacturer in China that produces a variety of nonwoven wipe products for personal and household applications. All of the conditions submitted to the TSX Venture Exchange in the press release dated October 1, 2007 have been met. The Company's name will officially change to Beijing Marvel Cleaning Supplies Co. Ltd., and will trade under the new symbol "BMW" on the TSX Venture Exchange.

As consideration for the acquisition of Beijing Marvel, the Company issued 129,673,548 shares to Scitech Industries & Trading Inc. ("Scitech"). Scitech now has control and direction over a total of 129,673,548 common shares (representing 59% of the outstanding shares) of Toba. Scitech advises that it does not have any intention of acquiring any further securities of the Issuer through market purchases. An Early Warning Report will be filed with Canadian Securities Commissions in respect of the acquisition. A copy of the report may be obtained from SEDAR at www.sedar.com.

The Company paid a total of 2,180,555 shares as finder's fees in connection with the acquisition to arm's length parties.

The 129,673,586 shares issued to Scitech and the 2,180,555 shares issued for the finder's fees will be subject to escrow.

In connection with the reverse takeover, 200,000 shares were issued as payment of a sponsorship fee to Bolder Investment Partners, Ltd.

Upon the completion of the reverse takeover the Company will be issuing 1,351,111 shares to Quest Pharmatech Inc. ("Quest") pursuant to an agreement between Beijing Marvel and Quest dated December 21, 2007, as amended, for the purchase of certain patents and patent applications which make up the Bionex Technology.

Toba is pleased to announce the completion of the previously announced non-brokered private placement (June 5, 2008) of 9,503,717 units, each unit consisting of one share at $.135 cents and one full warrant exercisable at $.27, having been issued for proceeds of $1,283,002. Finder's fees will be paid to eligible finders in relation to this financing, all in accordance to regulatory policies.

The proceeds of the financing will go toward the completion of the new manufacturing facility and working capital for the Company.

The private placement of units are in addition to the previously completed private placements of 16,480,436 special warrants, each special warrant is automatically exercised for one unit upon the completion of the acquisition, for gross proceeds of $2,224,858.86. In connection with the above noted private placements of units and special warrants, 25,984,153 shares and 25,984,153 share purchase warrants were issued.

Mr. Robert Dzisiak, Chairman of the board stated, "We are extremely pleased to complete this phase of the company's reorganization. The new manufacturing facility is near completion and will be the largest wipes manufacturing plant in Asia. We would like to congratulate Mr. Liao Yongliang, company founder and CEO, for his efforts, in building Beijing Marvel into the premier wipes manufacturer in China. We look forward to executing our business plan and reorganizing a successful brand into the leading provider of fast moving consumer cleansing products in China."

About Beijing Marvel

Beijing Marvel was incorporated as a wholly owned foreign enterprise (WOFE) in Beijing, China in 2003. Beijing Marvel was the first to introduce wet wipes to the Chinese market over a decade ago. Its award-winning brand, "Dreamboat", has been a leading brand in China. Beijing Marvel has traditionally manufactured and sold a family of nonwoven wipe products for personal and household applications. Beijing Marvel currently develops and produces nonwoven wet wipes for both domestic and international markets under the brand name "Dreamboat". Beijing Marvel produces unique wipe products in a range of sizes and containers and the current product line includes universal and generic wipes, sterilizing wipes, baby wipes, cleaning wipes and feminine hygiene wipes.

Robust management and an exclusive national distribution network of 80 distributors, has made Beijing Marvel the number one brand in China with its portfolio of wipe products now sold in over 20,000 outlets including Wal-Mart and Carrefour's stores across China. A large scale expansion of the existing business is currently underway with a new 100,000 sq. ft. manufacturing facility that, upon completion, will be the largest wipes manufacturing facility in Asia. Beijing Marvel will be applying proprietary designed and manufactured production equipment to produce wipe products more efficiently and at lower costs than traditional equipment outsourced by competitors. Beijing Marvel and its exclusive distribution network will be integrated to produce a single production and national distribution network, improving efficiency and reducing costs. By internalizing our distribution network, it will act as one unit rather than 80 separate entities. Further cost reduction efficiencies will be realized with the installation of retail point-of-sale information sharing interfaces.

Through the reorganization and large-scale expansion of an existing, successful brand, Beijing Marvel will significantly lower costs and bring retail pricing down to a point significantly below its competitor's pricing. This sustainable, lowest pricing model will be used to take and retain market share from competitors in the world's largest, price sensitive, growth market. The goal of the Company is to become one of the largest manufacturers and distributors of fast moving consumer goods in China.

The global wipes industry is a highly competitive business where participants employ a variety of competitive strategies to build and retain market share. These strategies include the development of new products, extension of product lines and product differentiation. The fundamental part of our competitive strategy involves the establishment of a very low-cost position, where we will compete primarily on the basis of price. This strategy is appropriate and representative of our tactics to be a store brand wipe, which competes very well against national brands by offering our high quality products at much lower cost.

Board of Directors

As a result of the shareholder vote at the Special Meeting of Shareholders held on September 19th, 2008, the new Board of Directors will be fixed at 6 as follows:

Robert Dzisiak - Chairman and Director: Former president of Refco Canada, former president of CFG Financial Group and past Chairman of and served as a director of the Winnipeg Commodities Exchange. Mr. Dzisiak is also the chairman of Wildcat Exploration and a director of Hilltop Resources Inc.

Liao Yongliang - CEO and Director: Founder of Beijing Marvel. Prior to introducing wet wipes and establishing Beijing Marvel's lead position in China, Mr. Liao was a film producer and successfully operated an advertising company and a trading firm.

Loren Currie - Secretary and Director: Mr. Currie has over 20 years experience holding executive corporate positions in the Canadian public markets.

Yang Jie (Jack) - Director: Mr. Yang has several years experience in Canadian public markets and doing business in China. Mr. Yang currently serves as a director of Continental Minerals, a Canadian public company with business interests in China.

Zhang Yunkun (William) - Director: Mr. Zhang will provide supervisory oversight for Beijing Marvel's operations in China.

Ms. Zhou Hang - Director: Ms. Zhou Hang is responsible for internal controls and financial reporting for Beijing Marvel's operations in China.

Stock Options Issued

In accordance to the Company's stock option plan, the company has issued 12,660,964 options, issued to certain officers, directors and employees of the Company. A further 9,249,121 options are available for issuance.

Further Financings

The Company announces that it is pursuing further financings which when finalized will be announced as they occur.

ON BEHALF OF THE BOARD OF DIRECTORS

Loren Currie, Director

Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the future, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in preclinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products; decisions, and the timing of decisions, made by regulatory agencies regarding approval of our technology and products; and the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the securities commission. Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the content of this press release.

Contacts: Toba Industries Ltd. Loren Currie Director (604) 646-5612 (604) 688-1817 (FAX)